Table 1. Panel of cell radiosensitivity and mutation status.
| Cell Line | SF2 | KRas | p53 | Keap1 |
| HBEC 3KT | 0.487 | wt | wt | wt |
| HBEC 3KT + KRas V12 | 0.474 | X | wt | wt |
| HBEC 3KT + KRas V12 +sh p53 | 0.650 | X | X | wt |
| HBEC 3KT + KRasV12 +sh p53 + myc | 0.702 | X | X | wt |
| HBEC 30KT | 0.442 | wt | wt | - |
| HCC 4017 | 0.321 | mut | mut (C833A) | wt |
| A549 | 0.771 | mut (G34A) | wt | mut (G333C);constitutive Nrf2 activation |
| H2009 | 0.615 | mut (G35C) | mut (G818T) | wt |
| HCC 2429 | 0.514 | wt | mut (G800A) | wt |
| HCC 15 | 0.484 | wt | mut (A776T) | wt |
| H23 | 0.053 | mut | mut | mut; Nrf2 still inducible |
| HME1 | 0.528 | wt | wt | wt |
| HMEC 50 | 0.659 | wt | mut | - |
| MDA-MB-231 | 0.452 | mut (G38A) | mut (G839A) | wt |
A summary of all cell lines used in the present study. Surviving fraction of cells at 2 Gy (SF2) is used as a metric of radio-sensitivity, with SF2>0.6 considered a “resistant” line and SF2<0.4 considered a “sensitive” line. Mutation status of KRas, p53, and Keap1/Nrf2 is listed as either wildtype (wt) or mutated (mut) as determined by full exon sequencing (John Minna and Adi Gazdar, UT-Southwestern Medical Center, Dallas, TX, personal communications). A mutation is present in Keap1 in the NSCLC H23 cell line (personal communications with Brandon Probst, Reata Pharmaceuticals). “X” indicates experimentally manipulated gene expression.